Asset Management One Co. Ltd. Sells 1,414 Shares of Solventum Corporation $SOLV

Asset Management One Co. Ltd. decreased its position in Solventum Corporation (NYSE:SOLV) by 2.3% during the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 60,080 shares of the company’s stock after selling 1,414 shares during the period. Asset Management One Co. Ltd.’s holdings in Solventum were worth $4,556,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Chelsea Counsel Co. boosted its holdings in Solventum by 720.7% in the second quarter. Chelsea Counsel Co. now owns 10,595 shares of the company’s stock valued at $804,000 after acquiring an additional 9,304 shares in the last quarter. ST Germain D J Co. Inc. boosted its holdings in Solventum by 84.6% in the second quarter. ST Germain D J Co. Inc. now owns 825 shares of the company’s stock valued at $63,000 after acquiring an additional 378 shares in the last quarter. CX Institutional boosted its holdings in Solventum by 11.7% in the second quarter. CX Institutional now owns 2,376 shares of the company’s stock valued at $180,000 after acquiring an additional 249 shares in the last quarter. ORG Wealth Partners LLC bought a new stake in Solventum in the second quarter valued at $71,000. Finally, Public Employees Retirement System of Ohio boosted its holdings in Solventum by 0.9% in the second quarter. Public Employees Retirement System of Ohio now owns 63,719 shares of the company’s stock valued at $4,832,000 after acquiring an additional 583 shares in the last quarter.

Analyst Ratings Changes

Several analysts recently weighed in on SOLV shares. UBS Group initiated coverage on shares of Solventum in a report on Wednesday, October 1st. They issued a “neutral” rating and a $77.00 price target on the stock. Zacks Research upgraded shares of Solventum from a “hold” rating to a “strong-buy” rating in a report on Monday, September 15th. Argus upgraded shares of Solventum from a “hold” rating to a “buy” rating and set a $90.00 target price on the stock in a report on Tuesday, July 1st. Wall Street Zen cut shares of Solventum from a “strong-buy” rating to a “buy” rating in a report on Tuesday, September 9th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Solventum in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $84.89.

Solventum Price Performance

NYSE SOLV opened at $71.04 on Wednesday. Solventum Corporation has a one year low of $60.70 and a one year high of $85.92. The stock has a 50-day moving average of $72.62 and a 200 day moving average of $72.28. The company has a market capitalization of $12.32 billion, a price-to-earnings ratio of 32.89, a PEG ratio of 2.92 and a beta of 0.50. The company has a debt-to-equity ratio of 2.14, a quick ratio of 0.86 and a current ratio of 1.22.

Solventum (NYSE:SOLV) last released its quarterly earnings results on Thursday, August 7th. The company reported $1.69 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.45 by $0.24. The business had revenue of $2.16 billion during the quarter, compared to the consensus estimate of $2.12 billion. Solventum had a return on equity of 29.93% and a net margin of 4.52%.The business’s quarterly revenue was up 3.8% compared to the same quarter last year. During the same period in the previous year, the company posted $1.56 EPS. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. On average, sell-side analysts forecast that Solventum Corporation will post 6.58 EPS for the current year.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.